Matthew Blackman

“Maybe John or Lee, could you just maybe talk about some of the areas, perhaps, of friction in the pharmacy transition process that you're finding and, you know, maybe whether there have been any surprises, good or bad in that discovery process, you know, relative to the full year guide you gave, just the conviction…”

“And, Yvonne, I just wanted to drill down a little bit on some of your latter comments in response to Larry's question, and specifically on the hip market. It was a noisy quarter in the hip market. globally, everyone's growth decelerated with the exception of Zimmer Biomet.”

“And maybe just to start quickly, Preston, just hoping for a little bit more color on the Nari supply shortfall. How much of an organic drag was it? Our math, it could have been 50 to 75 basis points.”

“So I guess this is not really a fair question, but I do need to ask it. In the context of the LRP guys, 2027, I feel confident, comfortable today reaffirming that billion-dollar revenue number.”

“And welcome to the, I was told, 46th annual TD Cowan Healthcare Conference, almost as old as I am. And I'm thrilled today to have with us the senior leadership from OrthoFix.”